Glycemic Variability: Prognostic Impact on Acute Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

340 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-30

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter observational clinical study in patients with acute ischemic stroke. The main objective is to evaluate the impact of glycemic variability (GV) on stroke outcome (mortality, functional recovery) of patients with acute ischemic stroke. Glycemic variability will be assessed using a subcutaneous device for continuous glycaemia motorization during 96 hours; also capillar glycaemia will be measured every 6 hours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glycemia and Ischemia Reperfusion Brain Injury in Patients With Acute Cerebral Infarction Treated With Mechanical Thrombectomy

NCT05871502

Cerebral Infarction

UNKNOWN NA

Glycaemic Variability in Acute Stroke

NCT04521634

Diabetes Mellitus, Type 1 Acute Stroke

COMPLETED

Hyperglycemia in Patients with Stroke and Indication of Enteral Nutrition

NCT03422900

Hyperglycaemia (Non Diabetic) Enteral Feeding Intolerance Stroke

COMPLETED NA

Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke

NCT02054429

Ischemic Stroke

COMPLETED PHASE1

Efficacy and Safety of Continuous Intravenous Versus Usual Subcutaneous Insulin in Acute Ischemic Stroke

NCT00472381

Acute Stroke Acute Cerebral Ischemia

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

10 different hospitals in Spain will participate in this study, recruiting a total of 340 patients. Once the informed consent form is signed, the subcutaneous device for continuous glycaemia motorization will be implanted and demographic, comorbidities and treatments of every patient will be registered. During the first 96 hours, capillar glycaemia, NIHSS scale, HbA1C levels, cerebral recanalization treatment and glycaemia correcting treatments will also be reported. In the following days (7, 30 and 90 days after stroke) modified Rankin Scale, NIHSS scale and stroke secondary prevention treatments will be evaluated. At day 90, a new measure of HbA1C will be done.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Ischemia Hyperglycemia Glycemic Variability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years old
* Inclusion less than 24 hours from ischemic stroke
* Functional independence prior to stroke
* Signed informed consent

Exclusion Criteria

* Transient cerebral ischemia
* Prevision of need to perform a magnetic resonance within the first 96 hours from inclusion
* Concomitant severe or deadly disease that may interfere with study follow-up during 3 months from stroke
* Current drug or alcohol abuse that may interfere with study follow-up
* Participation in a clinical trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No